We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-16.00 | -0.15% | 10,862.00 | 10,902.00 | 10,906.00 | 10,948.00 | 10,802.00 | 10,850.00 | 2,221,596 | 16:35:29 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 28.38 | 169.03B |
Date | Subject | Author | Discuss |
---|---|---|---|
26/11/2020 00:42 | Expert raises flag over the 'shaky science' behind Oxford's Covid jab and claims data behind promising vaccine 'was patched together and doesn't include many over-55s' | philanderer | |
25/11/2020 18:44 | Doctors warn side effects from pfizer's and monderna's Covid vaccine shots won't be 'walk in the park' Side effects are Covid symptoms. | coxsmn | |
25/11/2020 17:39 | AZN in a bear market at the close, perhaps a short lived one and explained by the parabolic spike over £100. | essentialinvestor | |
25/11/2020 16:48 | There's always tomorrow ;-) | bountyhunter | |
25/11/2020 16:42 | Though I didn't manage to get all of them :-) | ashwani01 | |
25/11/2020 16:41 | There is the big seller 1,136,301 at 7800p. Been driving the price down all day. Am happy to be in at 7801. | ashwani01 | |
25/11/2020 11:30 | GregB, Yes filled now. Was hoping the drop through £79.44 was quick in the hope that they would be slow to execute and get an even better price, sadly not. Hopefully will be a good entry price though. GLA | gary1966 | |
25/11/2020 10:49 | montyhedge. AZN will only sell the vaccine at cost until the pandemic is dealt with. After that they will charge the market price to a very grateful world. The AZN vaccine will have secured a global reputation as the coronavirus vaccine of choice AZN shares will rocket. | daijavu | |
25/11/2020 10:44 | From the AZN RNS: One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen (n=8,895) showed 62% efficacy when given as two full doses at least one month apart. The combined analysis from both dosing regimens (n=11,636) resulted in an average efficacy of 70%. More data will continue to accumulate and additional analysis will be conducted, refining the efficacy reading and establishing the duration of protection. An independent Data Safety Monitoring Board determined that the analysis met its primary endpoint showing protection from COVID-19 occurring 14 days or more after receiving two doses of the vaccine. No serious safety events related to the vaccine have been confirmed. AZD1222 was well tolerated across both dosing regimens. AstraZeneca will now immediately prepare regulatory submission of the data to authorities around the world that have a framework in place for conditional or early approval. The Company will seek an Emergency Use Listing from the World Health Organization for an accelerated pathway to vaccine availability in low-income countries. | daijavu | |
25/11/2020 10:39 | I would not worry about COVID vaccine, non profit making anyway. Good for science not for the shares. | montyhedge | |
25/11/2020 10:39 | Should have got filled this time around. | gregb | |
25/11/2020 10:01 | Left an order a couple of days ago to buy 500 at £79.44. Has hit that level today but annoyingly the order wasn’t filled. Hopefully will get another bite at the cherry but feeling a bit peed off at the moment. | gary1966 | |
25/11/2020 08:35 | For clarity, there wasn't a '1 dose trial'. One set had a half dose followed by a full dose - 90% efficacy. The other group had two full doses - 62% efficacy. Combine all the data and it averaged at 70% - but obviously they'll go for the 90% method and even aim to improve on that. | bluemango | |
25/11/2020 08:25 | The numbers in the 1 dose trial were vastly greater than the 11/2 dose, which skewed the average down . | stoaty1 | |
25/11/2020 08:14 | There were two trials run alongside each other. The same vaccine but to different regimens. One trial gave 90% efficacy. The 70% was the average of both. Unfortunately, the media chose to report the 70% i assume that when the vaccine used it will follow the regimen that gave the 90% Allowing for margins of error that always occur, this vaccine might prove to be just as effective as Pfizer's but with fewer problems with storage and distribution and cost. | daijavu | |
25/11/2020 07:54 | I've read its possibly 100% effective in eradicating the virus totally from the UK via a mixture of herd immunity and vaccine efficacy. | netcurtains | |
25/11/2020 07:51 | "There seems to be a lot of disinformation about this vaccine" preceded by "70% effective is what I've read and 90% once the second dose has been given" The irony is, er, significant... 🙄 | imastu pidgitaswell | |
24/11/2020 21:43 | 70% effective is what I've read and 90% once the second dose has been given. To put it in context the flu vaccine given every year is about 40-60% effective. The vaccine is also much easier to store than the other two vaccines and much cheaper. And even better AZN has a significant stake in the Moderna vaccine company. There seems to be a lot of disinformation about this vaccine which is odd. Perhaps people are trying to drive the price down - who knows. I for one am not disappointed and happy to hold until the market gets AZN's real potential and will enjoy the yield in the meantime. | mercury123 | |
24/11/2020 20:29 | monty, the flu vaccine is only about 60% effective I think . montyhedge24 Nov '20 - 09:10 - 3099 of 3127 0 0 2 This vaccine I think is a disappointment, 2 jabs one month apart | arja | |
24/11/2020 19:32 | Slaoui said in the next two to three weeks the U.S. would learn more about the immune response generated by the Astra-Oxford vaccine, and would better understand why the lower dose resulted in a more significant response And separately on Twitter 3 hours ago: *SLAOUI SAYS ASTRA PHASE 3 TRIAL IN U.S. MAY BE COMPLETED SOON | bluemango | |
24/11/2020 17:49 | https://www.streetin | montyhedge | |
24/11/2020 16:16 | games, interesting question. Unfortunately it may be the opposite on oncology with failures in diagnosis of early stage cancers leading to more aggressive treatment options. The flipside is very late stage diagnosis may leave only palliative care. Would expect UK excess deaths to remain elevated for a number of years. One of my friends is a cancer nurse at a hospital in Guildford and the golden rule is ...if you are experiencing new, unexplained symptoms for 3 weeks then see a GP. Don't delay. | essentialinvestor | |
24/11/2020 16:03 | question:- Am happily invested here but would love to know who else are the significant listed players in the covid-19 quick (1/2 hour ?)tests . And same question regarding the antibody tests. Who are the significant names in the antibody testing field? Many thanks | undervaluedassets | |
24/11/2020 14:41 | Also quick question to investors. With all the delay in treatments due to hospital cancellations and people who should, but don't seek gp attention etc, will this cause a loss in revenue for azn. I can imagine a lot of countries worldwide will be experiencing same as uk. | games | |
24/11/2020 14:36 | That's a different discussion really. The end result is still the same. | essentialinvestor |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions